Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rosanne Barker

Neurology Knoxville, TN Medical Doctor

NPI 1780624486 CMS profile 1097205

1388 Papermill Pointe Way, Knoxville, TN 37909

Open in the dashboard

General payments

$40,407

197 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rosanne Barker of Knoxville, TN is reported in the CMS Open Payments database as having received $40,407 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,958 52
2024 General $8,470 29
2023 General $18,334 55
2022 General $675 19
2021 General $462 15
2020 General $123 7
2019 General $383 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rosanne Barker
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rosanne Barker were reported at $11,958. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rosanne Barker Neurology median Middle half National median
2019 $383 $474 $118–$2,177 $163
2020 $123 $367 $82–$2,309 $114
2021 $462 $438 $104–$2,547 $132
2022 $675 $442 $103–$2,388 $149
2023 $18,334 $464 $119–$2,312 $160
2024 $8,470 $468 $119–$2,323 $164
2025 $11,958 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $38,130 134 payments
  2. Axsome Therapeutics, Inc. $809 28 payments
  3. Inspire Medical Systems, Inc. $573 10 payments
  4. Avadel CNS Pharmaceuticals, LLC $420 3 payments
  5. Harmony Biosciences LLC $233 8 payments
  6. Resmed Corp $91 6 payments
  7. UCB, Inc. $69 3 payments
  8. Lilly USA, LLC $32 2 payments
  9. Aytu BioScience, Inc $22 1 payment
  10. Arbor Pharmaceuticals, Inc. $15 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,456 4 payments
  2. Travel and Lodging $5,906 22 payments
  3. Food and Beverage $5,172 161 payments
  4. Education $522 8 payments
  5. Consulting Fee $350 2 payments
Products named General payments · program years 2019–2025
  1. XYWAV $37,386 108 payments
  2. Sunosi Neurology $718 27 payments
  3. XYREM $458 19 payments
  4. INSPIRE $360 9 payments
  5. LUMRYZ $319 2 payments
  6. Inspire Upper Airway Stimulation System $213 1 payment
  7. SUNOSI Pain $203 5 payments
  8. Wakix $200 7 payments
  9. SUNOSI Neurology $83 5 payments
  10. Neupro $69 3 payments
  11. Other $206 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

2,161

Median for Neurology: 833

Drug cost

$2,048,931

Median for Neurology: $202,670

Branded share of claims

33.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 90 $1,651,888
Wakix Pitolisant Hcl Brand 13 $190,540
Sunosi Solriamfetol Hcl Brand 81 $113,945
Modafinil Generic 285 $33,552
Belsomra Suvorexant Brand 26 $16,795
Zaleplon Generic 154 $7,740
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 416 $6,967
Armodafinil Generic 58 $5,994
Ipratropium Bromide Generic 81 $5,047
Doxepin Hcl Generic 148 $3,366

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$187,262

Medicare's payments for the services billed

Medicare patients

261

Average age 71

Services billed

1,261

122 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 41%
Depression 31%
Ischemic heart disease 27%
Chronic kidney disease 23%
Atrial fibrillation 18%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
$8,301 90 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record